Mn Services Vermogensbeheer B.V. Trims Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Mn Services Vermogensbeheer B.V. decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 2.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 60,900 shares of the life sciences company’s stock after selling 1,500 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Illumina were worth $7,942,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. UMB Bank n.a. raised its position in Illumina by 7.0% in the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after acquiring an additional 88 shares during the period. Integrated Advisors Network LLC raised its stake in shares of Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after buying an additional 90 shares during the period. Texas Permanent School Fund Corp lifted its position in shares of Illumina by 0.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock valued at $4,507,000 after buying an additional 114 shares in the last quarter. Institute for Wealth Management LLC. lifted its position in shares of Illumina by 4.6% during the 2nd quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock valued at $285,000 after buying an additional 119 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Up 1.0 %

Shares of ILMN stock opened at $154.96 on Wednesday. The company has a market cap of $24.69 billion, a PE ratio of -15.56 and a beta of 1.13. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $156.66. The stock’s 50 day simple moving average is $136.87 and its two-hundred day simple moving average is $122.92. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 EPS. Research analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the topic of several analyst reports. TD Cowen lifted their price target on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird upped their target price on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. Leerink Partners upped their price objective on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $120.00 to $154.00 in a research note on Friday, August 16th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average price target of $161.50.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.